GET DAILY SIGNALSSutro Biopharma (STRO) Drops -43% Over 30 Days: Key Factors Behind the Move
Key Takeaways
- Sutro Biopharma shares declined roughly 43% over the 30 days ending October 30, 2026, falling from a $16.11 close on September 30 to around $9.10.
- The slide picked up speed in mid-October, highlighted by a 17.1% single-day drop on October 13 that took place without any company announcement or SEC filing.
- Wider risk-off sentiment in small-cap biotech, fueled by higher Treasury yields and proposed Treasury scrutiny of U.S. investment in Chinese biotech, added to the pressure.
- The company is in a post-restructuring phase centered on its next-generation ADC pipeline after deprioritizing its former lead program, luvelta, in 2025.
- Analyst opinions are mixed: several firms kept Buy or Outperform ratings, while independent services moved to Sell.
- Investors can review detailed Price Targets, Earnings data, and Forecast pages for more context on STRO.
Sutro Biopharma (STRO) Company Overview and Market Position
Sutro Biopharma, Inc. is a clinical-stage oncology company focused on designing and developing antibody-drug conjugates (ADCs) and novel biologic formats. Its technology relies on the XpressCF cell-free protein synthesis platform and the XpressCF+ site-specific conjugation platform, which provide precise control over drug payload placement and ratios. After a strategic portfolio review in March 2025, Sutro restructured operations—cutting its workforce by about two-thirds, exiting internal GMP manufacturing, and moving to external manufacturing—to focus resources on wholly owned next-generation ADC programs, starting with STRO-004, an exatecan ADC targeting Tissue Factor. The company also licenses assets such as STRO-003 (a ROR1-targeting ADC) to Ipsen, and its platforms support partners including PCVX. I follow STRO mainly for its ADC pipeline, differentiated conjugation technology, and cash runway outlook. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Sutro Biopharma (STRO) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, STRO fell approximately 43%, moving from a closing price of $16.11 on September 30, 2026, to about $9.10 by the October 30 close. The selloff unfolded gradually rather than in one session, though it included a sharp 17.1% drop on October 13 that took shares to $11.01. The stock kept sliding through the rest of the month, approaching its 52-week low of $7.15.
The quarterly picture shows even steeper pressure. Three months earlier, on July 31, 2026, shares closed at $24.17, so the stock has dropped roughly 62% over the last quarter. This extended de-rating reflects ongoing pressure rather than isolated swings, with the 50-day and 200-day moving averages well above current levels and market capitalization compressed to roughly $150 million.
What Drove STRO Stock Price in the Last 30 Days
The 30-day decline stemmed less from one fundamental catalyst than from a mix of positioning, sentiment, and sector forces. The standout move was the October 13 drop of 17.1%, which happened without any company announcement, SEC filing, or reported news—a sign the move reflected selling pressure rather than fresh disclosure.
That pressure grew alongside a broader risk-off tone in speculative biotech. In late October, small-cap biotech peers weakened amid elevated Treasury yields, a technology-led market selloff, and uncertainty around the Treasury’s proposed curbs on U.S. investment in Chinese biotech. STRO, with a beta near 1.49 and limited near-term revenue, felt this shift in risk appetite acutely. Ratings activity also shaped sentiment: Weiss Ratings downgraded Sutro Biopharma to a “Sell (E+)” designation on October 19, while H.C. Wainwright reiterated a Buy with a $50 target on October 16 and Wedbush reiterated Outperform with a $60 target on October 15. These bullish calls did not stop the slide, highlighting the strength of negative market sentiment.
What Drove STRO Stock Performance Over the Last Quarter
The longer three-month decline reflects investors re-rating a clinical-stage company in transition. On August 12, Sutro reported second-quarter results that missed expectations: revenue of $9.84 million came in below the roughly $11.96 million consensus estimate and fell 84.57% year over year, while the quarterly loss widened. The revenue drop ties to the winding down of prior collaboration economics after the 2025 restructuring and the deprioritization of the luvelta program.
The restructuring itself stays central to the quarterly story. By shifting focus to preclinical, wholly owned assets such as STRO-004, the company reduced headcount and exited internal manufacturing—moves that lower costs but also trim near-term clinical catalysts and revenue visibility. Combined with a cash-intensive development model, these factors have kept the stock under sustained pressure even as several analysts maintain long-term price targets well above the current share price. From what I see, this transition phase is important because it changes the risk-reward profile investors are pricing in.
STRO Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, several factors are likely to shape STRO’s path. The next quarterly earnings report, estimated for November 9, 2026, will draw attention for updates on cash runway, collaboration revenue, and any new pipeline milestones. Progress toward an investigational new drug (IND) filing for STRO-227, the company’s dual-payload PTK7-targeting ADC, is another key catalyst flagged for the second half of 2026.
Beyond company-specific events, investors should track broader biotech sentiment, interest-rate movements, and any regulatory developments around cross-border biotech investment, given their recent impact on small-cap valuations. Pipeline data disclosures, partnership activity, and analyst target revisions will also matter. These considerations are informational and are not intended as investment recommendations. I’m watching this closely as the setup evolves.
Exploring AI Tools for Market Analysis
In my work tracking volatile names such as STRO, I find Tickeron’s Trending AI Robots page useful for spotting systematic trading signals. It highlights a curated selection of the platform’s top-performing automated trading bots across different strategies, timeframes, and performance metrics, helping users compare approaches that fit various risk profiles and styles. This focused view can serve as a practical reference when evaluating momentum in names like this one.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
STRO in +5.48% Uptrend, growing for three consecutive days on October 20, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where STRO advanced for three days, in 209 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 18 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
STRO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on STRO as a result. In 74 of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for STRO turned negative on October 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 43 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where STRO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for STRO entered a downward trend on October 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.460) is normal, around the industry mean (3.154). P/E Ratio (-0.524) is within average values for comparable stocks, (-1.071). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.299) among similar stocks. P/S Ratio (3.982) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. STRO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STRO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of new products in protein vaccines and therapeutics
Industry Biotechnology
Advertisement